PolyNovo Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

PolyNovo hat ein Gesamteigenkapital von A$72.1M und eine Gesamtverschuldung von A$2.6M, wodurch sich der Verschuldungsgrad auf 3.6% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen A$108.7M bzw. A$36.6M. PolyNovo Das EBIT des Unternehmens beträgt A$897.0K, so dass der Zinsdeckungsgrad -1.1 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von A$46.0M.

Wichtige Informationen

3.6%

Verhältnis von Schulden zu Eigenkapital

AU$2.63m

Verschuldung

Zinsdeckungsgrad	-1.1x
Bargeld	AU$45.96m
Eigenkapital	AU$72.12m
Gesamtverbindlichkeiten	AU$36.60m
Gesamtvermögen	AU$108.72m

Jüngste Berichte zur Finanzlage

Recent updates

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Oct 10

PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

Aug 28

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Aug 06

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

May 08

When Should You Buy PolyNovo Limited (ASX:PNV)?

Feb 28

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Feb 02

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17

Analyse der Finanzlage

Kurzfristige Verbindlichkeiten: PNVDie kurzfristigen Aktiva des Unternehmens (A$79.3M) übersteigen seine kurzfristigen Passiva (A$23.2M).

Langfristige Verbindlichkeiten: PNVDie kurzfristigen Vermögenswerte des Unternehmens (A$79.3M) übersteigen seine langfristigen Verbindlichkeiten (A$13.3M).

Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital

Verschuldungsgrad: PNV über mehr Barmittel verfügt als seine Gesamtverschuldung.

Schulden abbauen: PNVDas Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 0% auf 3.6% gestiegen.

Schuldendeckung: PNVDie Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (140%).

Zinsdeckung: PNV mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.

PolyNovo Balance Sheet Health

Finanzielle Gesundheit Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Berichte zur Finanzlage

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

Recent updates

Is It Time To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 21% undervalued

Independent Non-Executive Director recently sold AU$261k worth of stock

PolyNovo Limited Announces Retirement of Bruce Rathie as Non-Executive Director

Non-Executive Independent Director recently sold AU$1.9m worth of stock

Now 21% undervalued

PolyNovo Limited, Annual General Meeting, Oct 28, 2024

PolyNovo (ASX:PNV) Is Experiencing Growth In Returns On Capital

Now 20% undervalued

Price target increased by 7.0% to AU$2.53

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 24% undervalued

Price target increased by 8.8% to AU$2.37

Consensus EPS estimates increase by 15%

PolyNovo Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Insufficient new directors

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 21% undervalued

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Consensus forecasts updated

Now 21% undervalued

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Independent Non-Executive Chairman recently bought AU$956k worth of stock

Now 23% undervalued

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

Independent Non-Executive Chairman recently bought AU$434k worth of stock